Drugs & Medical Devices
Get ready for the next wave of pharmaceutical litigation with HarrisMartin's Drugs & Medical Devices. This reporter will keep you one step ahead of drug and medical device litigation with in-depth investigations, guest commentaries and objective courtroom coverage on today's and tomorrow's hottest drugs and supplements.
SEARCH THE ARCHIVES
Issue #3, March 2002
A New Jersey district court has set a loose schedule of events for its consolidated Rezulin litigation following a recent case management conference
The complaint alleges that the defendants concealed their knowledge of the flaw and significantly downplayed the addiction risks of OxyContin
The federal court in New York overseeing Rezulin multidistrict litigation has set forth guidelines to ensure that certain documents produced by clinical investigators
Plaintiffs in a Metabolife 356 Case Fail to Establish Predominance, District Court Denies Class Certification
According to a Jan. 25 decision, the plaintiffs' request for class certification in a Metabolife 356 product liability case has been denied because predominance was not established.
A Jan. 28 lawsuit alleges that the S.C. doctors and pharmacists that prescribed OxyContin, along with the companies that manufacture and distribute the drug, caused the plaintiffs to suffer death, addiction and withdrawal symptoms.
Parties in a case that alleged an arthritis drug was contaminated with a beta blocker, causing the plaintiff to suffer from an overdose
To ensure that confidential documents are afforded adequate protection, the federal court overseeing Rezulin multidistrict litigation has outlined requirements
A trial court has found that a plaintiff's breach of express warranty and unfair trade practices claims against Johnson & Johnson and Janssen
Judge Lewis Kaplan of the U.S. District Court for the Southern District of New York has ordered that deposition testimony of current and former Warner-Lambert employees
After only one hour of deliberation, the six-person jury returned a verdict in favor of defendant Pfizer Inc., which acquired Warner-Lambert after Rezulin was withdrawn from the market